Clinical Trials & Medical Discoveries

19 Jan, 2024, 13:38 ET Tampa General Hospital First in Florida, One of the First in the Nation to Administer New Gene Therapy for Patients with Hemophilia B

Tampa General Hospital (TGH) announced that the TGH Cancer Institute recently completed Florida's first successful infusion of Hemgenix, a gene...

19 Jan, 2024, 08:50 ET CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic...

19 Jan, 2024, 08:31 ET Pusan National University's Breakthrough in Muscle Regeneration: Nanotech Scaffolding Supports Tissue Growth

Tissue engineering, which involves the use of grafts or scaffolds to aid cell regeneration, is emerging as a key medical practice for treating...

19 Jan, 2024, 08:15 ET Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients...

19 Jan, 2024, 07:30 ET Endo Announces New Data for Dupuytren's Contracture Presented at the American Association for Hand Surgery Annual Meeting

Endo International plc (OTC: ENDPQ) announced today that two new presentations related to Dupuytren's contracture and XIAFLEX® (collagenase...

19 Jan, 2024, 06:57 ET Michael E. DeBakey VA Medical Center VA Hospital announces New Cell Therapy Clinical Trial for Amyotrophic Lateral Sclerosis

Michael E. DeBakey VA Medical Center announces opening of a new clinical trial using CK0803- off-the-shelf, allogeneic T regulatory cells that have...

19 Jan, 2024, 05:50 ET Octapharma stellt auf dem 17. Jahreskongress der European Association for Haemophilia and Allied Disorders (EAHAD), der vom 6. bis 9. Februar 2024 in Frankfurt stattfindet, klinische und wissenschaftliche Daten vor, die unser Verständnis und unsere Behandlung von Blutungsstörungen voranbringen

18 Jan, 2024, 17:49 ET Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for...

18 Jan, 2024, 13:00 ET BPS Issues Call for Petition in Pharmacy Informatics

The Board of Pharmacy Specialties® (BPS), the post-licensure certification organization serving the pharmacy profession, issues a call for petition...

18 Jan, 2024, 10:03 ET Octapharma présentera des données cliniques et scientifiques qui font progresser notre compréhension et notre traitement des troubles hémorragiques lors du 17e congrès annuel de l'Association européenne pour l'hémophilie et les troubles apparentés (EAHAD), qui se tiendra à Francfort, en Allemagne, du 6 au 9 février 2024

18 Jan, 2024, 09:00 ET Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott (NYSE: ABT) today announced the first global procedures have been conducted using the company's new Volt™ Pulsed Field Ablation (PFA) System...

18 Jan, 2024, 08:33 ET Healing Heel Pain: Researchers from Sahmyook University Explore the Use of Local Vibration in Plantar Fasciitis Treatment

Plantar fasciitis (PF) is a common musculoskeletal, inflammatory condition, characterized by severe pain in the heel of the foot, to the extent that...

18 Jan, 2024, 08:20 ET Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug...

18 Jan, 2024, 08:08 ET Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024

Eisai announced today the presentation of research in renal cell carcinoma (RCC) during the 2024 American Society of Clinical Oncology (ASCO)...

18 Jan, 2024, 08:00 ET Evommune Announces Initiation of a Phase 1 Trial of its MRGPRX2 Antagonist for the Treatment of Chronic Spontaneous Urticaria

Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today...

18 Jan, 2024, 07:00 ET Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related...

18 Jan, 2024, 06:55 ET PeproMene Bio, Inc. annonce la rémission complète du premier patient de la cohorte 1 traité dans le cadre de son essai clinique de phase 1 sur la leucémie lymphoblastique aiguë à cellules B (B-ALL) récidivant et réfractaire avec le PMB-CT01 (cellules T BAFFR-CAR) à City of Hope

18 Jan, 2024, 05:15 ET ASCO GI 2024: Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients

Golden Biotechnology Corp. (TPEX 4132) ("GoldenBiotech", GBC), an advanced biopharmaceutical drug development company, had unveiled the findings of...

18 Jan, 2024, 04:03 ET PeproMene Bio, Inc. anuncia la remisión completa del primer paciente en el ensayo clínico de PMB-CT01